Open AccessEffects of Teriparatide, Alendronate, or Both on Bone Turnover in Osteoporotic Men
Author(s) -
Joel S. Finkelstein,
Benjamin Z. Leder,
SherriAnn M. BurnettBowie,
Jason J. Wyland,
Hang Lee,
Amanda Victoria de la Paz,
Kate Gibson,
Robert M. Neer
Publication year - 2006
Publication title -
the journal of clinical endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.206
H-Index - 353
eISSN - 1945-7197
pISSN - 0021-972X
DOI - 10.1210/jc.2006-0190
Subject(s) - teriparatide , bone remodeling , osteoporosis , medicine , osteoporotic fracture , dentistry , bone density conservation agents , endocrinology , bone mineral
We have previously demonstrated that alendronate reduces the ability of teriparatide to increase bone mineral density (BMD) in osteoporotic men. The underlying basis for this observation is poorly understood.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom